Medigene AG: Medigene AG Expands Patent Portfolio with Patent Grant for its MAGE-A4 Targeted T Cell Receptor in China

Planegg/Martinsried (pta020/05.12.2024/11:00 UTC+1)

Planegg/Martinsried, December 5, 2024. Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced that the Chinese Patent Office has granted a patent for its T cell receptor (TCR) targeting MAGE-A4, a well-recognized and validated cancer-testis antigen, expressed in multiple tumor types.

"We are delighted to receive the patent grant for our MAGE-A4-targeted TCR in China. This TCR currently serves as the main component of a T cell receptor engineered T cell (TCR-T) therapy in a clinical trial in Greater China in advanced solid tumors conducted by Regeneron's collaborator JW Therapeutics," said Selwyn Ho, CEO at Medigene AG. "Importantly, this broadens the opportunity to deploy our optimal affinity 3S (sensitive, specific, and safe) TCRs on a global scale. These TCRs can be utilized across various TCR-guided modalities, including off-the-shelf TCR-guided T cell engagers, TCR-T therapies, and TCR natural killer cell therapies."

Medigene consistently enhances and broadens its patent portfolio by generating novel 3S TCRs, incorporating new technologies and extending existing patents into additional jurisdictions. The Company currently holds more than 29 distinct patent families globally, safeguarding its 3S TCRs and exclusive E2E Platform technologies.

--- end of press release ---

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that can be utilized in multiple therapeutic modalities, such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit https://medigene.com/

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.com
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate